NCT06947291View on ClinicalTrials.gov

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

PHASE2RecruitingINTERVENTIONAL

Enrollment

350

Participants

Timeline

Start Date

June 4, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

October 30, 2027

Conditions

Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

Interventions

DRUG

Glumetinib Tablets

glumetinib once daily once daily under fasting conditions in each 21-day treatment cycle.

DRUG

Docetaxel for Injection (Albumin-bound)

Docetaxel for Injection (Albumin-bound) by intravenous injection in each 21-day treatment cycle.

Trial Locations (1)

Unknown

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT06947291 - Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors | Biotech Hunter | Biotech Hunter